Large-scale US trial of AZ vaccine: 79% protection, 100% protection against severe disease

Reuters and other foreign newspapers reported on the 22nd that the results of a large clinical trial of the Wuhan pneumonia (novel coronavirus disease, COVID-19) vaccine (hereinafter referred to as AZ vaccine) developed by Astellicom and the University of Oxford in the United States have been released, with 79% protection against symptomatic infection and 100% protection against the risk of serious illness and death.

According to the report, Astellicom released the data on the 22nd, and said that an independent vaccine safety investigation committee, with the assistance of neurologists, specifically examined the thrombosis of 21,583 subjects who received at least one dose of the vaccine in the large U.S. trial, including the very rare cerebral deep vein and sinus thrombosis (CVST), and showed that the risk of thrombosis or similar thrombosis did not increase. The results showed no increased risk of thrombosis or similar thrombosis, and no CVST was observed. The results are expected to be a first step toward approval of the AZ vaccine by U.S. authorities.

Prior to the release of this data, the European Medicines Agency (EMA) and the World health Organization (WHO) also confirmed the safety of the AZ vaccine after a rigorous review, stating that the benefits of vaccination outweighed the risks, and many countries have resumed administration.